Mohsen Nosratabadi

Mr. Mohsen Nosratabadi

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2020 in Journal of Rehabilitation
Verified
Journal Article
Closed access
PDF file
APAyoub Parno
Ayoub Parno
KSKourosh Sayehmiri
Kourosh Sayehmiri
RAReza Nabi Amjad
Reza Nabi Amjad
RIReyhaneh Ivanbagha
Reyhaneh Ivanbagha
MAMir Mohammad Hosseini Ahagh
Mir Mohammad Hosseini Ahagh
MNMohsen Nosratabadi
Mohsen Nosratabadi
Objective: Work-related musculoskeletal disorders are one of the major causes of lost working time, increased costs, human injuries and burnout. The International Labor Organization estimates that about 160 million work-related illnesses occur worldwide each year, where the highest prevalent illnesses are musculoskeletal disorders. Several studies have been conducted In Iran to investigate the prevalence of these disorders, each providing different statistics. Therefore, considering the importance of these disorders, it is necessary to obtain accurate results with high statistical power and validate them. The aim of this study was to investigate the prevalence of work-related musculoskeletal disorders in Iran in order to obtain more accurate results by conducting a meta-analysis. Materials & Methods: For this meta-analysis, searching was conducted in SID, MagIran, IranMedex, Google Scholar, Scopus, Web of Science, and PubMed databases using the keyword “work-related musculoskeletal disorders“ in both Persian and English on studies conducted during 2001-2016 in various cities of Iran. Inclusion criteria were: investigating the prevalence of musculoskeletal disorders in a period of one year, being a cross-sectional or descriptive-analytical study, publication in Persian or English, availability of full-texts, assessment using standard methods (e.g. Nordic Musculoskeletal Questionnaire) and considering the prevalence of musculoskeletal disorders throughout the body (upper and lower extremities). The heterogeneity of the articles was evaluated using the I2 statistics and the data were analyzed in STATA software using meta-analysis and random-effects model. Results: In this study, 45 papers on work-related musculoskeletal disorders were studied. The overall sample size of these studies was 9813, with a mean number of 218 for each study. Most of studies were descriptive-analytical and cross-sectional. In all of them, the prevalence of musculoskeletal disorders in different parts of the body had been investigated. According to their results, the most prevalent work-related musculoskeletal disorder in lower extremity was low back pain (0.49%) and in upper extremity, it was neck pain (39.3%). The prevalence of musculoskeletal disorders in other parts of the body were 39.32% in the neck, 36.9% in shoulders, 36.8% in the back, 34% in the wrist, 26.9% in legs, 20.5% in thighs and hips, and 16.2% in elbows.

4 July 2022 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
MNMohsen Nosratabadi
Mohsen Nosratabadi
JAJavad Akhtari
Javad Akhtari
LFLeila Faeli
Leila Faeli
IHIman Haghani
Iman Haghani
SASeyed Reza Aghili
Seyed Reza Aghili
MAMahdi Abastabar
Mahdi Abastabar
Fusarium species are filamentous fungi that cause a variety of infections in humans. Because they are commonly resistant to many antifungal drugs currently available in clinical settings, research into alternative targets in fungal cells and therapeutic approaches is required. The antifungal activity of miltefosine and four comparators, amphotericin B, voriconazole, itraconazole, and caspofungin, were tested in vitro against a collection of susceptible and resistant clinical (n = 68) and environmental (n = 42) Fusarium isolates. Amphotericin B (0.8 μg/mL) had the lowest geometric mean (GM) MICs/MECs values followed by miltefosine (1.44 μg/mL), voriconazole (2.15 μg/mL), caspofungin (7.23 μg/mL), and itraconazole (14.19 μg/mL). Miltefosine was the most effective agent against Fusarium isolates after amphotericin B indicating that miltefosine has the potential to be studied as a novel treatment for Fusarium infections.

19 April 2025 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
Robab Ebrahimi BaroghRobab Ebrahimi Barogh
Robab Ebrahimi Barogh
SRSeyyed Mobin Rahimnia
Seyyed Mobin Rahimnia
MNMohsen Nosratabadi
Mohsen Nosratabadi
AMAbolfazl Maleki
Abolfazl Maleki
FEFatemeh Khosravi Ebrahimi
Fatemeh Khosravi Ebrahimi
Hamid BadaliHamid Badali
Hamid Badali
Background: Trichophyton indotineae terbinafine-resistant infections are emerging in healthy individuals. Luliconazole, an imidazole antifungal that is effective against skin infections, faces challenges due to low water solubility and poor skin penetration. This study aimed to formulate a luliconazole-loaded nanostructured lipid-carrier (NLC) gel in a Carbopol-based system to enhance drug absorption and efficacy in a guinea pig model of dermatophytosis. Methods: Luliconazole-loaded nanostructured lipid carriers (NLCs) were prepared using a solvent evaporation method and gel formulation. Skin absorption and retention were assessed via Franz diffusion cells. The antifungal efficacy was tested against T. indotineae in thirty guinea pigs with induced tinea corporis, divided into five treatment groups. Mycological, clinical, and histopathological evaluations were conducted, along with skin irritation studies for safety. Results: LCZ-NLC demonstrated significantly better skin penetration than simple luliconazole gel, with cumulative drug penetration of 71.8 ± 3.7 μg/cm2 versus 50.9 ± 4.2 μg/cm2 after 24 h. Both formulations achieved complete infection resolution after 21 and 28 days, with reduced inflammation and no local irritations. On day 21, the LCZ-NLC 1% gel significantly reduced lesion scores and mycological evidence of infection compared to the terbinafine-treated groups, untreated controls, and NLC-gel-treated group (p < 0.05). Histopathological analysis indicated a reduction in both epidermal thickening and fungal burden in the models that received treatment with the LCZ-NLC 1% gel. Conclusions: Luliconazole-loaded lipid carriers enhance drug absorption and efficacy, suggesting shorter treatment durations and improved patient outcomes for resistant fungal infections. However, further studies are warranted to correlate these findings with clinical outcomes.

28 October 2024 in Diagnostic Microbiology and Infectious Disease
Verified
Journal Article
Closed access
IHIman Haghani
Iman Haghani
SHSeyedeh Mahdieh Hashemi
Seyedeh Mahdieh Hashemi
MAMahdi Abastabar
Mahdi Abastabar
ZYZahra Yahyazadeh
Zahra Yahyazadeh
RERobab Ebrahimi-Barough
Robab Ebrahimi-Barough
HBHamid Badali
Hamid Badali

25 July 2024 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
Robab Ebrahimi BaroghRobab Ebrahimi Barogh
Robab Ebrahimi Barogh
Javad JavidniaJavad Javidnia
Javad Javidnia
ADAli Davoodi
Ali Davoodi
FAFereshteh Talebpour Amiri
Fereshteh Talebpour Amiri
MMMaryam Moazeni
Maryam Moazeni
Hamid BadaliHamid Badali
Hamid Badali
Candida auris, an emerging non-albicans multidrug-resistant yeast, has become a significant cause of invasive candidiasis in healthcare settings. So far, data on the metabolites of C. auris in different clades are minimal, and no studies have focused on clade V metabolites. Therefore, Gas chromatography–mass spectrometry (GC-MS) was used for the metabolomic profiling of clade I C. auris compared with fluconazole-resistant and susceptible C. auris in clade V strains. GC-MS chromatography revealed 28, 22, and 30 compounds in methanolic extracts of the fluconazole-susceptible and fluconazole-resistant C. auris clade V and C. auris clade I strain, respectively. Some compounds, such as acetamide and metaraminol, were found in fluconazole-susceptible and resistant C. auris clade V and clade I. N-methyl-ethanamine and bis(2-ethylhexyl) phthalate metabolites were found in both fluconazole -susceptible and resistant C. auris clade V, as well as 3-methyl-4-isopropylphenol, 3,5-bis(1,1-dimethyl)-1,2-benzenediol, and diisostyl phthalate metabolites in both fluconazole resistant C. auris clade V and I. Identifying these metabolites contributes to understanding the morphogenesis and pathogenesis of C. auris, highlighting their potential role in antifungal drug resistance and the control of fungal growth. However, further experiments are warranted to fully comprehend the identified metabolites’ regulatory responses, and there may be potential challenges in translating these findings into clinical applications.

21 April 2026 in Journal of Clinical Laboratory Analysis
Verified
Journal Article
Open access
ZYZahra Yahyazadeh
Zahra Yahyazadeh
ZHZeynab Haseli
Zeynab Haseli
Javad JavidniaJavad Javidnia
Javad Javidnia
MAMahdi Abastabar
Mahdi Abastabar
ENEisa Nazar
Eisa Nazar
Hamid BadaliHamid Badali
Hamid Badali
Background: Naganishia diffluens (formerly Cryptococcus diffluens ) is a non‐neoformans cryptococcal species rarely isolated as a human pathogen. We reported a case of oral cryptococcosis caused by N. diffluens for the first time and reviewed relevant literature. Methods: Herein, we present the case of a 31‐year‐old Iranian male with a history of major β‐thalassemia, who presented with non‐hemorrhagic white spots on the buccal mucosa, the mouth, lips, and the tongue's surface. Abdominal ultrasound results of the pelvis and abdomen showed that the patient has significant splenomegaly. Two consecutive samples were collected from the white spots on the patient's tongue to confirm the infection, which was confirmed via PCR Sequencing analysis. Results: In both sampling occasions, Naganishia diffluens was isolated as the causative organism. According to a review conducted in PubMed, Web of Science, and Scopus for data analysis of oral cryptococcosis, just 27 reports were described in the literature. Naganishia diffluens can be the causative agent of some infections. Conclusion: This is the first report of oral cryptococcosis due to N. diffluens successfully detected by DNA sequencing. However, to understand the precise prevalence of this emerging pathogen, epidemiological surveillance studies are highly recommended.